Researchers at the Columbia University Medical Center in New York (United States) have just made a welcome discovery for the millions of men who have complexes about their baldness worldwide. They found that Ruxolitinib, a drug usually used to treat myelofibrosis (a chronic disease characterized by the progressive development of fibrosis in the bone marrow) had a surprising effect on baldness in 3 test patients: in 5 months, they regained the hair of their youth when they had previously only 2/3 of their hair on the scalp.
This discovery was announced in the digital edition of the scientific journal Nature Medicine Journal by the team of researchers at Columbia who had previously identified the cells responsible for the destruction of hair follicles in cases of alopecia areata. This pathology which causes hair loss in patches is an autoimmune disease characterized by the destruction of hair follicles by the immune system.
If this new treatment is encouraging for people suffering from alopecia areata, it is however not valid for the majority of male baldness which has a hormonal origin.
